Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma

2018252 citationsJournal Article

Authors

Hideaki Takahashi · Mita Hospital

Yuichiro Tada · Mita Hospital

Takashi Saotome · Matsudo City Hospital

Kohei Akazawa · Niigata University Medical and Dental Hospital

Hiroya Ojiri · Jikei University School of Medicine

Chihiro Fushimi · Mita Hospital

Tatsuo Masubuchi ·

Abstract

Our data show encouraging efficacy of trastuzumab plus docetaxel therapy in patients with human epidermal growth factor receptor 2-positive SDC, with a manageable toxicity profile.

Topics & Keywords

Salivary Gland Tumors Diagnosis and Treatment Ear and Head Tumors Cancer and Skin Lesions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 37, Issue 2, pp. 125-134

DOI: 10.1200/jco.18.00545

Field-Weighted Citation Impact: 18.26